[For example,] a patient whose main issue is inflammation might benefit more from the anti-inflammatory effect of the drug than a patient whose Crohn's disease has led to strictures, [or] a narrowing of the intestine. The Takeaway GLP-1s decrease inflammation throughout the body, and may improve Crohns disease outcomes
& Volkow, N
32 The SOUL trial evaluated oral semaglutide in patients with T2D who had established atherosclerotic cardiovascular disease, chronic kidney disease (CKD), or both
Keep all medications out of reach of children and pets, preferably in a designated medication area
Results All of the injured rats that received BPC 157 exhibited consistent clinical improvement, increasingly better motor function of the tail, no autotomy, and resolved spasticity by day 15
1 Some have theorized that GLP-1 medications may affect metabolic pathways, potentially altering thyroid hormone production